

Supplementary Materials

Title: Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma

James Wu, MSc, MPH,¹ Armin Ghobadi, MD,² Richard Maziarz, MD,³ Krish Patel, MD,⁴ Hil Hsu, PhD, MPH,¹ Zihao Liu, MSPH,⁵ Caitlin Sheetz, MPH,⁵ Peter Kardel, MA,⁵ Christine Fu, PhD¹

¹Kite, A Gilead Company, Santa Monica, CA, USA; ²Washington University School of Medicine, St. Louis, MO; ³Oregon Health and Science University, Portland, OR; ⁴Swedish Cancer Institute, Seattle, WA; ⁵ADVI Health, Washington, DC

Corresponding Author: James Wu

Email: jwu9@kitepharma.com

Supplement Table 1: ICD-PCS and HCPCS Codes

Product Group	ICD-PCS Code	Descriptor
Lisocabtagene Maraleucel	XW23376	Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach
	XW24376	Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach
	XW033N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach
	XW043N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach
Tisagenlecleucel	XW033J7	Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach
	XW043J7	Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach
Axicabtagene Ciloleucel	XW033H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach
	XW043H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach

Product Group	HCPCS Code	Descriptor
Lisocabtagene Maraleucel	C9076	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
	Q2054	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Tisagenlecleucel	Q2040	Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
	Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells,

Axicabtagene Ciloleucel		including leukapheresis and dose preparation procedures, per therapeutic dose
----------------------------	--	--